A drug for irritable bowel syndrome (IBS) which was linked to the deaths of at least five patients, within nine months of being licensed, may soon be back on the market.
A drug for irritable bowel syndrome (IBS) which was linked to the deaths of at least five patients, within nine months of being licensed, may soon be back on the market.